Alternatives to vancomycin in treating methicillin-resistant Staphylococcus aureus infections

Journal of Antimicrobial Chemotherapy

Volumn 41, Issue 3, 1998, Pages 325-328

  Rahman, Mustafiz ^a  

^a KING S MILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; VANCOMYCIN;

ARTICLE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; HUMANS; METHICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 0031946719     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/41.3.325     Document Type: Article

References (35)

1. Martin, M. A. (1994). Methicillin-resistant Staphylococcus aureus: the persistent nosocomial pathogen. Current Clinical Topics in Infectious Diseases 14, 170-91.
2. Keane, C. T. (1993). Methicillin-resistant Staphylococcus aureus (MRS A). Irish Medical Journal 86, 151-64.
3. Hiramatsu, K., Hanaki, H., Ino, T., Yabuta, K., Oguri, T. & Tenover, F. C. (1997). Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy 40, 135-6.
4. Martin, R. & Wilcox, K. R. (1997). Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. Morbidity and Mortality Weekly Report 46, 765.
5. Richardson, J. F., Quoraishi, A. H. M., Francis, B. J. & Marples, R. R. (1990). Beta-lactamase-negative, methicillin-resistant Staphylococcus aureus in a newborn nursery: report of an outbreak and laboratory investigations. Journal of Hospital Infection 16, 109-21.
6. Zaher, A., al-Thawadi, S. & Cimola, N. (1997). β-Lactamase negative, methicillin-resistant Staphylococcus aureus lacking the mecA gene determinant. Journal of Antimicrobial Chemotherapy 39, 108-9.
7. Moreillon, P. (1995). Amoxycillin-clavulanate versus methicillin or isoxazolyl penicillins for treatment of Staphylococcus aureus infections. Journal ofAntimicrobial Chemotherapy 35, 435-41.
8. Rahman, M. (1987). Treatment of superficial infection or colonisation with methicillin-resistant Staphylococcus aureus (MRSA) by various topical and systemic antimicrobials. In Progress in Antimicrobial and Anti-cancer Chemotherapy. (Berkarda, B. & Keumele, H. P., Eds), Vol. 1, pp. 578-80. Ecomed Publishers, Londsberg/Lech.
9. Cox, R. A., Conquest, C., Mallaghan, C. & Marples, R. R. (1995). A major outbreak of methicillin-resistant Staphylococcus aureus caused by a new phage type (BMRSA-16). Journal of Hospital Infection 29, 87-106.
10. Combined Working Party of the British Society for Antimicrobial Chemotherapy and the Hospital Infection Society. (1995). Guidelines on the control of methicillin-resistant Staphylococcus aureus in the community. Journal of Hospital Infection 31, 1-12.
11. Riley, T. V. & Rouse, I. L. (1995). Methicillin-resistant Staphylococcus aureus in Western Australia, 1983-1992. Journal of Hospital Infection 29, 177-88.
12. Kono, K. & Arakawa, K. (1995). Methicillin-resistant Staphylococcus aureus (MRSA) isolated in clinics and hospitals in the Fukuoka city area. Journal of Hospital Infection 29, 265-73.
13. Scheel, O., Lyon, D. J., Rosdahl, V. T., Adeyemi-Doro, F. A. B., Ling, T. K. W. & Cheng, A. F. B. (1996). In-vitro susceptibility of isolates of methicillin-resistant Staphylococcus aureus 1988-1993. Journal of Antimicrobial Chemotherapy 37, 243-51.
14. Andrews, J. M. & Wise, R. (1994). The in-vitro activity of a new semi-synthetic streptogramin compound, RP 59500, against staphylococci and respiratory pathogens. Journal of Antimicrobial Chemotherapy 33, 849-53.
15. Shonekan, D., Handwerger, S. & Mildvan, D. (1997) Comparative in-vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against Gram-positive bacteria. Journal of Antimicrobial Chemotherapy 39, 405-9.
16. Weiss, W. J., Jacobus, N. V., Petersen, P. J. & Testa, R. T. (1995). Susceptibility of enterococci, methicillin-resistant Staphylococcus aureus and Streptococcus pneumoniae to the glycylcyclines. Journal of Antimicrobial Chemotherapy 36, 225-30.
17. Jorgensen, J. H., McElmeel, M. L. & Trippy, C. W. (1997). In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species. Antimicrobial Agents and Chemotherapy 41, 465-7.
18. Jones, R. N., Barrett, M. S. & Erwin, M. E. (1997). In-vitro activity and spectrum of LY333328, a novel glycopeptide derivative Antimicrobial Agents and Chemotherapy 41, 488-93.
19. Mercier, R. C., Houlihan, H. H. & Ryback, M. J. (1997) Pharmacodynamic evaluation of a new glycopeptide, LY 333328, and in-vitro activity against Staphylococcus aureus and Enterococcus faecium. Antimicrobial Agents and Chemotherapy 41, 1307-12.
20. Takahashi, Y., Masuda, N., Otsuki, M., Miki, M. & Nishino, T. (1997). In vitro activity of HSR-903, a new quinolone. Antimicrobial Agents and Chemotherapy 41, 1326-30.
21. Cohen, M. A., Huband, M. D., Gage, J. W., Yoder, S. L., Roland, G. E. & Gracheck, S. J. (1997). In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin. Journal of Antimicrobial Chemotherapy 40, 205-11.
22. Malanoski, G., Collins, L., Eliopoulos, C. T., Moellering, R. C. & Eliopoulos, G. M. (1995). Comparative in-vitro activities of L-695,256, a novel carbapenem against gram-positive bacteria. Antimicrobial Agents and Chemotherapy 39, 990-5.
23. Sumita, Y., Nouda, H., Kamazawa, K. & Fukasawa, M. (1995). Antimicrobial activities of SM-17466, a novel carbapenem antibiotic with potent activity against methicillin-resistant Staphylococcus aureus. Antimicrobial Agents and Chemotherapy 39, 910-6.
24. Kato, Y., Otsuki, M. & Nishino, T. (1997). Antibacterial properties of BO-2727, a new carbapenem antibiotic. Journal of Antimicrobial Chemotherapy 40, 195-203.
25. Van Laethem, Y., Hermans, P., De Wit, S., Goosens, H. & Clumeck, N. (1988). Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results. Journal of Antimicrobial Chemotherapy 21, Suppl. A, 81-7.
26. Wood, M. J. (1996). The comparative efficacy and safety of teicoplanin and vancomycin. Journal of Antimicrobial Chemotherapy 37, 209-22.
27. Mulligan, M. E., Murray-Leisure, K. A., Ribner, B. S., Standiford, H. C., John, J. F., Korvick, J. A. etal. (1993). Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis and epidemiology with implications for prevention and management. American Journal of Medicine 94, 313-28.
28. Matsumoto, T., Kubo, S., Haraoka, M., Takahashi, K., Tanaka, M., Sakumoto, M. et al. (1993). Combination chemotherapy of infection due to methicillin-resistant Staphylococcus aureus with combination therapy by cefuzonam and fosfomycin or minocycline in the urologic field. Clinical Therapeutics 15, 819-28.
29. Kono, K., Takeda, S., Tatara, I., Arakawa, K., Tanaka, H., Miyaké, S. et al. (1994). Combined therapy with arbekacin and fosfomycin for methicillin-resistant Staphylococcus aureus infections. Japanese Journal of Antibiotics 47,789-803.
30. Markowitz, N., Quinn, E. L & Saravolatz, L. D. (1992), Trimethoprim-sulphamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Annals of Internal Medicine 117, 390-8.
31. Gottlieb, R. D., Shah, M. K., Perlman, D. C. & Kimmelman, C. P. (1992). Community-acquired methicillin-resistant Staphylococcus aureus infections in otolaryngology. Otolaryngology-Head and Neck Surgery 107,434-7.
32. Torralba, M. D., Frey, S. E. & Lagging, L. M. (1995) Treatment of methicillin-resistant Staphylococcus. aureus infection with quinupristin/dalfopristin. Clinical Infectious Diseases 21, 460-1.
33. Griswold, M. W., Lomaestro, B. M. & Briceland, L. L. (1996). Quinupristin-dalfopristin (RP 59500): an injectable streptogramin combination. American Journal of Health System Pharmacy 53, 2045-53.
34. Nichols, R. (1997). Randomized, comparative, multicenter, open study of quinupristin/dalfopristin (Q/D, RP 59500:synercid) versus standard therapy (Oxacillin or Vancomycin) in the treatment of complicated Gram-positive skin and skin structure infections (C-SSSI). In Program and Abstracts of the 20th International Congress of Chemotherapy, Sydney, 1997. Abstract 2314.
35. Beal, J. (1997). Randomized, comparative, multicentre, open study of quinupristin/dalfopristin (Q/D, RP 59500, Synercid) versus standard therapy (Cefazolin or Vancomycin) in the treatment of complicated Gram-positive skin and skin structure infections (C-SSSI). In Program and Abstracts of the 20th International Congress of Chemotherapy, Sydney, 1997. Abstract 2316.